Loading patent…
AssigneeSoligenix, Inc.
InventorsOreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
Estimating the term…
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
A method of reducing the incidence, severity and/or duration of oral mucositis in a subject who has been exposed to a damaging amount of radiation or chemotherapeutic agents, comprising administering to the patient an effective amount of:
A method of treating an individual suffering from a disease selected from the group consisting of mucositis and colitis or exposure to acute radiation comprising administering to the individual a peptide consisting of an amino acid sequence of SED ID Nos:
Dependencies are inferred from the claim text.